Literature DB >> 17452610

Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging.

Steffen E Petersen1, Michael Jerosch-Herold, Lucy E Hudsmith, Matthew D Robson, Jane M Francis, Helen A Doll, Joseph B Selvanayagam, Stefan Neubauer, Hugh Watkins.   

Abstract

BACKGROUND: Microvascular dysfunction in hypertrophic cardiomyopathy (HCM) may create an ischemic substrate conducive to sudden death, but it remains unknown whether the extent of hypertrophy is associated with proportionally poorer perfusion reserve. Comparisons between magnitude of hypertrophy, impairment of perfusion reserve, and extent of fibrosis may offer new insights for future clinical risk stratification in HCM but require multiparametric imaging with high spatial and temporal resolution. METHODS AND
RESULTS: Degree of hypertrophy, myocardial blood flow at rest and during hyperemia (hMBF), and myocardial fibrosis were assessed with magnetic resonance imaging in 35 HCM patients (9 [26%] male/26 female) and 14 healthy controls (4 [29%] male/10 female), aged 18 to 78 years (mean+/-SD, 42+/-14 years) with the use of the American Heart Association left ventricular 16-segment model. Resting MBF was similar in HCM patients and controls. hMBF was lower in HCM patients (1.84+/-0.89 mL/min per gram) than in healthy controls (3.42+/-1.76 mL/min per gram, with a difference of -0.95+/-0.30 [SE] mL/min per gram; P<0.001) after adjustment for multiple variables, including end-diastolic segmental wall thickness (P<0.001). In HCM patients, hMBF decreased with increasing end-diastolic wall thickness (P<0.005) and preferentially in the endocardial layer. The frequency of endocardial hMBF falling below epicardial hMBF rose with wall thickness (P=0.045), as did the incidence of fibrosis (P<0.001).
CONCLUSIONS: In HCM the vasodilator response is reduced, particularly in the endocardium, and in proportion to the magnitude of hypertrophy. Microvascular dysfunction and subsequent ischemia may be important components of the risk attributable to HCM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452610     DOI: 10.1161/CIRCULATIONAHA.106.657023

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  115 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  Exercise in hypertrophic cardiomyopathy.

Authors:  Sharlene M Day
Journal:  J Cardiovasc Transl Res       Date:  2009-10-14       Impact factor: 4.132

Review 3.  The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy.

Authors:  Mouaz H Al-Mallah; Mohammad Naseem Shareef
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

4.  3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.

Authors:  Liang Yin; Hai-Yan Xu; Sui-Sheng Zheng; Ying Zhu; Jiang-Xi Xiao; Wei Zhou; Si-Si Yu; Liang-Geng Gong
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-13       Impact factor: 2.357

Review 5.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

Review 6.  Cardiovascular magnetic resonance in heart failure.

Authors:  Theodoros D Karamitsos; Stefan Neubauer
Journal:  Curr Cardiol Rep       Date:  2011-06       Impact factor: 2.931

Review 7.  Three-dimensional contrast-enhanced and non-contrast-enhanced cardiac magnetic resonance imaging for the assessment of myocardial ischemic reactions: the practice of looking deeply into the myocardium.

Authors:  Cosima Jahnke; Sebastian Kozerke; Bernhard Schnackenburg; Nikolaus Marx; Ingo Paetsch
Journal:  J Nucl Cardiol       Date:  2011-10       Impact factor: 5.952

8.  Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy.

Authors:  Michael Jerosch-Herold; David C Sheridan; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Diana Dutton; Rami Alharethi; Duanxiang Li; Ray E Hershberger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

9.  Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study.

Authors:  Deborah H Kwon; Randolph M Setser; Zoran B Popović; Maran Thamilarasan; Srikanth Sola; Paul Schoenhagen; Mario J Garcia; Scott D Flamm; Harry M Lever; Milind Y Desai
Journal:  Int J Cardiovasc Imaging       Date:  2008-01-19       Impact factor: 2.357

10.  The role of urate and xanthine oxidase in vascular oxidative stress: future directions.

Authors:  Jacob George; Allan Struthers
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.